British Airways Pensions Investment Management Ltd Maintains Position in Amgen Inc. (AMGN)
British Airways Pensions Investment Management Ltd maintained its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 128,690 shares of the medical research company’s stock at the end of the second quarter. British Airways Pensions Investment Management Ltd’s holdings in Amgen were worth $19,658,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Oakworth Capital Inc. raised its position in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN raised its position in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC raised its position in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the period. Vigilant Capital Management LLC raised its position in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares during the period. Finally, Evanson Asset Management LLC acquired a new position in shares of Amgen during the second quarter worth about $211,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded up 0.32% on Monday, hitting $167.34. The stock had a trading volume of 2,514,609 shares. The stock has a market cap of $125.23 billion, a price-to-earnings ratio of 17.12 and a beta of 0.94. The stock’s 50 day moving average is $171.51 and its 200 day moving average is $161.44. Amgen Inc. has a one year low of $138.06 and a one year high of $176.85.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.58 billion. During the same period in the prior year, the business earned $2.57 earnings per share. The business’s revenue was up 5.9% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post $11.36 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were given a $1.00 dividend. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 annualized dividend and a dividend yield of 2.39%. Amgen’s dividend payout ratio is currently 40.90%.
A number of research analysts have recently issued reports on the company. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $171.34 target price on the stock in a research report on Wednesday, August 3rd. Leerink Swann reiterated a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Credit Suisse Group AG set a $206.00 target price on Amgen and gave the company a “buy” rating in a research report on Saturday, September 17th. Robert W. Baird reiterated an “outperform” rating and set a $157.00 target price on shares of Amgen in a research report on Friday, August 26th. Finally, Citigroup Inc. increased their target price on Amgen from $165.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 29th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.